QQQ   333.06 (+0.81%)
AAPL   173.19 (+0.63%)
MSFT   293.47 (+0.53%)
META   180.89 (+0.22%)
GOOGL   122.08 (+0.33%)
AMZN   143.18 (-0.26%)
TSLA   927.96 (+3.10%)
NVDA   190.32 (+1.73%)
NIO   21.30 (+0.90%)
BABA   94.20 (-0.60%)
AMD   101.01 (+0.18%)
MU   64.70 (-0.52%)
T   18.39 (+0.66%)
CGC   3.82 (+15.76%)
GE   79.81 (-0.15%)
F   16.32 (+0.87%)
DIS   124.26 (+2.21%)
AMC   24.21 (-0.94%)
PYPL   101.51 (+0.41%)
PFE   49.75 (-0.72%)
NFLX   249.11 (-0.08%)
QQQ   333.06 (+0.81%)
AAPL   173.19 (+0.63%)
MSFT   293.47 (+0.53%)
META   180.89 (+0.22%)
GOOGL   122.08 (+0.33%)
AMZN   143.18 (-0.26%)
TSLA   927.96 (+3.10%)
NVDA   190.32 (+1.73%)
NIO   21.30 (+0.90%)
BABA   94.20 (-0.60%)
AMD   101.01 (+0.18%)
MU   64.70 (-0.52%)
T   18.39 (+0.66%)
CGC   3.82 (+15.76%)
GE   79.81 (-0.15%)
F   16.32 (+0.87%)
DIS   124.26 (+2.21%)
AMC   24.21 (-0.94%)
PYPL   101.51 (+0.41%)
PFE   49.75 (-0.72%)
NFLX   249.11 (-0.08%)
QQQ   333.06 (+0.81%)
AAPL   173.19 (+0.63%)
MSFT   293.47 (+0.53%)
META   180.89 (+0.22%)
GOOGL   122.08 (+0.33%)
AMZN   143.18 (-0.26%)
TSLA   927.96 (+3.10%)
NVDA   190.32 (+1.73%)
NIO   21.30 (+0.90%)
BABA   94.20 (-0.60%)
AMD   101.01 (+0.18%)
MU   64.70 (-0.52%)
T   18.39 (+0.66%)
CGC   3.82 (+15.76%)
GE   79.81 (-0.15%)
F   16.32 (+0.87%)
DIS   124.26 (+2.21%)
AMC   24.21 (-0.94%)
PYPL   101.51 (+0.41%)
PFE   49.75 (-0.72%)
NFLX   249.11 (-0.08%)
QQQ   333.06 (+0.81%)
AAPL   173.19 (+0.63%)
MSFT   293.47 (+0.53%)
META   180.89 (+0.22%)
GOOGL   122.08 (+0.33%)
AMZN   143.18 (-0.26%)
TSLA   927.96 (+3.10%)
NVDA   190.32 (+1.73%)
NIO   21.30 (+0.90%)
BABA   94.20 (-0.60%)
AMD   101.01 (+0.18%)
MU   64.70 (-0.52%)
T   18.39 (+0.66%)
CGC   3.82 (+15.76%)
GE   79.81 (-0.15%)
F   16.32 (+0.87%)
DIS   124.26 (+2.21%)
AMC   24.21 (-0.94%)
PYPL   101.51 (+0.41%)
PFE   49.75 (-0.72%)
NFLX   249.11 (-0.08%)
NASDAQ:SGMO

Sangamo Therapeutics - SGMO Stock Forecast, Price & News

$6.39
+0.06 (+0.95%)
(As of 08/15/2022 12:00 AM ET)
Add
Compare
Today's Range
$6.19
$6.42
50-Day Range
$3.28
$6.39
52-Week Range
$3.12
$11.49
Volume
2.01 million shs
Average Volume
1.53 million shs
Market Capitalization
$1.00 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.75

Sangamo Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
115.2% Upside
$13.75 Price Target
Short Interest
Bearish
8.20% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.19mentions of Sangamo Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
Acquiring Shares
$25,033 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.29) to ($1.30) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.90 out of 5 stars

Medical Sector

863rd out of 1,125 stocks

Biological Products, Except Diagnostic Industry

136th out of 179 stocks

SGMO stock logo

About Sangamo Therapeutics (NASDAQ:SGMO) Stock

Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.

Wall Street Analyst Weigh In

SGMO has been the subject of a number of research analyst reports. StockNews.com downgraded shares of Sangamo Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, June 11th. Wedbush reiterated a "neutral" rating and issued a $5.00 target price on shares of Sangamo Therapeutics in a research report on Monday, June 13th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $13.75.

Sangamo Therapeutics Stock Performance

SGMO Stock opened at $6.33 on Monday. The firm's 50-day moving average price is $4.41 and its two-hundred day moving average price is $4.89. Sangamo Therapeutics has a 12-month low of $3.12 and a 12-month high of $11.49.

Sangamo Therapeutics (NASDAQ:SGMO - Get Rating) last released its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.35) by $0.06. Sangamo Therapeutics had a negative net margin of 150.96% and a negative return on equity of 48.06%. The firm had revenue of $29.38 million for the quarter, compared to analysts' expectations of $24.63 million. During the same quarter in the previous year, the company earned ($0.33) earnings per share. The company's revenue for the quarter was up 5.4% compared to the same quarter last year. Equities research analysts anticipate that Sangamo Therapeutics will post -1.29 earnings per share for the current fiscal year.

Insider Buying and Selling at Sangamo Therapeutics

In related news, Director John Markels purchased 6,784 shares of Sangamo Therapeutics stock in a transaction that occurred on Friday, June 3rd. The shares were bought at an average price of $3.69 per share, for a total transaction of $25,032.96. Following the completion of the transaction, the director now directly owns 32,484 shares of the company's stock, valued at $119,865.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 2.60% of the company's stock.

Receive SGMO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sangamo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SGMO Stock News Headlines

Sangamo Therapeutics Inc - Stock Quote SGMO
NRDS, PTGX and SGMO are among after hour movers
Sangamo Therapeutics Tops Q1 EPS by 1c
Sangamo Therapeutics Q1 2022 Earnings Preview
Sangamo Therapeutics's Earnings: A Preview
Sangamo Therapeutics: Q4 Earnings Insights
See More Headlines
Receive SGMO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sangamo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SGMO Company Calendar

Last Earnings
8/04/2022
Today
8/15/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:SGMO
CUSIP
80067710
Employees
431
Year Founded
1995

Price Target and Rating

Average Stock Price Forecast
$13.75
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+115.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-178,290,000.00
Net Margins
-150.96%
Pretax Margin
-150.82%

Debt

Sales & Book Value

Annual Sales
$110.70 million
Book Value
$2.58 per share

Miscellaneous

Free Float
152,483,000
Market Cap
$1.00 billion
Optionable
Optionable
Beta
1.41

Social Links


Key Executives

  • Dr. Alexander D. Macrae Ch.B (Age 59)
    M.B., MRCP, Ph.D., CEO, Pres & Director
    Comp: $1.14M
  • Ms. Prathyusha Duraibabu CPA (Age 43)
    M.B.A., Sr. VP, CFO & Principal Accounting Officer
    Comp: $495.58k
  • Mr. D. Mark McClung (Age 59)
    Exec. VP & COO
    Comp: $617.96k
  • Dr. R. Andrew Ramelmeier Ph.D. (Age 60)
    Exec. VP of Technical Operations
    Comp: $651.27k
  • Dr. Robert J. Schott M.P.H. (Age 64)
    M.D., MPH, FACC, Sr. VP & Head of Devel.
    Comp: $628.87k
  • Dr. Jason D. Fontenot Ph.D. (Age 52)
    Sr. VP & Chief Scientific Officer
  • Ms. Aron Feingold
    Head of Corp. Communications & Investor Relations Officer
  • Mr. Scott B. Willoughby (Age 47)
    Sr. VP, Gen. Counsel & Corp. Sec.
  • Ms. Whitney Jones
    Sr. VP & Chief People Officer
  • Dr. Nathalie Dubois-Stringfellow
    Sr. VP of Product Devel. & Management













SGMO Stock - Frequently Asked Questions

Should I buy or sell Sangamo Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sangamo Therapeutics in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SGMO shares.
View SGMO analyst ratings
or view top-rated stocks.

What is Sangamo Therapeutics' stock price forecast for 2022?

4 brokers have issued 12 month price objectives for Sangamo Therapeutics' shares. Their SGMO share price forecasts range from $5.00 to $25.00. On average, they expect the company's share price to reach $13.75 in the next year. This suggests a possible upside of 115.2% from the stock's current price.
View analysts price targets for SGMO
or view top-rated stocks among Wall Street analysts.

How have SGMO shares performed in 2022?

Sangamo Therapeutics' stock was trading at $7.50 at the beginning of 2022. Since then, SGMO stock has decreased by 14.8% and is now trading at $6.39.
View the best growth stocks for 2022 here
.

When is Sangamo Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our SGMO earnings forecast
.

How were Sangamo Therapeutics' earnings last quarter?

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) issued its quarterly earnings results on Thursday, August, 4th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, beating analysts' consensus estimates of ($0.35) by $0.06. The biopharmaceutical company earned $29.38 million during the quarter, compared to analyst estimates of $24.63 million. Sangamo Therapeutics had a negative trailing twelve-month return on equity of 48.06% and a negative net margin of 150.96%. The company's quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter last year, the firm earned ($0.33) EPS.

What is Sandy Macrae, M.B., Ch.B., Ph.D.'s approval rating as Sangamo Therapeutics' CEO?

10 employees have rated Sangamo Therapeutics Chief Executive Officer Sandy Macrae, M.B., Ch.B., Ph.D. on Glassdoor.com. Sandy Macrae, M.B., Ch.B., Ph.D. has an approval rating of 89% among the company's employees.

What other stocks do shareholders of Sangamo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sangamo Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), CRISPR Therapeutics (CRSP), Novavax (NVAX), Gilead Sciences (GILD), Brainstorm Cell Therapeutics (BCLI), Editas Medicine (EDIT), Netflix (NFLX) and Intel (INTC).

What is Sangamo Therapeutics' stock symbol?

Sangamo Therapeutics trades on the NASDAQ under the ticker symbol "SGMO."

Who are Sangamo Therapeutics' major shareholders?

Sangamo Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Credit Suisse AG (2.42%), JPMorgan Chase & Co. (0.96%), Renaissance Technologies LLC (0.92%), Millennium Management LLC (0.77%), Northern Trust Corp (0.74%) and Nordea Investment Management AB (0.44%). Insiders that own company stock include Biogen Inc, Gary Loeb, H Stewart Parker, John Markels, Joseph S Zakrzewski, Rolf Andrew Ramelmeier, Saira Ramasastry and Stephen George Dilly.
View institutional ownership trends
.

How do I buy shares of Sangamo Therapeutics?

Shares of SGMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sangamo Therapeutics' stock price today?

One share of SGMO stock can currently be purchased for approximately $6.39.

How much money does Sangamo Therapeutics make?

Sangamo Therapeutics (NASDAQ:SGMO) has a market capitalization of $1.00 billion and generates $110.70 million in revenue each year. The biopharmaceutical company earns $-178,290,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis.

How many employees does Sangamo Therapeutics have?

The company employs 431 workers across the globe.

When was Sangamo Therapeutics founded?

Sangamo Therapeutics was founded in 1995.

How can I contact Sangamo Therapeutics?

Sangamo Therapeutics' mailing address is 7000 MARINA BLVD, BRISBANE CA, 94005. The official website for the company is www.sangamo.com. The biopharmaceutical company can be reached via phone at (510) 970-6000, via email at investor.relations@sangamo.com, or via fax at 510-236-8951.

This page (NASDAQ:SGMO) was last updated on 8/15/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.